Amount of income (expense) related to nonoperating activities, classified as other.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

License, and Funding Agreements - Additional Information (Detail) € in Millions		3 Months Ended		6 Months Ended
	Jan. 13, 2025 EUR (€)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)
Collaboration License And Funding Arrangements [Line Items]
Royalty expense		$ 100,000
Other (expense) income, net		(547,000)	$ 144,000	$ (442,000)	$ 249,000
Research and Development Incentive
Collaboration License And Funding Arrangements [Line Items]
Grant receivable		700,000		700,000
Other (expense) income, net		$ 0		0	$ 300,000
Genzyme Agreement
Collaboration License And Funding Arrangements [Line Items]
Royalty expense				4,500,000
Milestone payment				3,000,000.0
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments				10,000,000.0
Collaborative arrangement, rights and obligations, one time payment one				500,000
Collaborative arrangement, rights and obligations, one time payment two				1,500,000
Collaborative arrangement, rights and obligations, one time payment three				3,000,000.0
Collaborative arrangement, rights and obligations, cumulative threshold one				50,000,000.0
Collaborative arrangement, rights and obligations, cumulative threshold two				150,000,000.0
Collaborative arrangement, rights and obligations, cumulative net sales threshold three				$ 300,000,000.0
Genzyme Agreement \| 6% Net Sales
Collaboration License And Funding Arrangements [Line Items]
Revenue, performance obligation, percentage of net sale		0.06		0.06
Genzyme Agreement \| 10% Net Sales
Collaboration License And Funding Arrangements [Line Items]
Revenue, performance obligation, percentage of net sale		0.10		0.10
Genzyme Agreement \| 12% Net Sales
Collaboration License And Funding Arrangements [Line Items]
Revenue, performance obligation, percentage of net sale		0.12		0.12
Genzyme Agreement \| 15% Sublease Payments Received
Collaboration License And Funding Arrangements [Line Items]
Revenue, performance obligation, percentage of net sale		0.15		0.15
Genzyme Agreement, Regulatory Approval
Collaboration License And Funding Arrangements [Line Items]
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments				$ 5,000,000.0
Norgine Agreement
Collaboration License And Funding Arrangements [Line Items]
One-time upfront payment \| €	€ 28.5
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments receivable \| €	225.6
Regulatory Milestone
Collaboration License And Funding Arrangements [Line Items]
Regulatory milestone, revenue recognized \| €	0.5
Collaborative agreement, contingent Milestone payments receivable \| €	20.6
Commercial Milestone
Collaboration License And Funding Arrangements [Line Items]
Collaborative agreement, contingent Milestone payments receivable \| €	20.0
Sales Milestone
Collaboration License And Funding Arrangements [Line Items]
Collaborative agreement, contingent Milestone payments receivable \| €	€ 185.0